GLP-1 analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
MT-ND6 is a gene of the mitochondrial genome coding for the NADH-ubiquinone oxidoreductase chain 6 protein (ND6). The ND6 protein is a subunit of NADH dehydrogenase (ubiquinone), which is located in the mitochondrial inner membrane and is the largest of the five complexes of the electron transport chain. Variations in the human MT-ND6 gene are associated with Leigh's syndrome, Leber's hereditary optic neuropathy (LHON) and dystonia.
At 3%, calcium is the fifth most abundant element in the Earth's crust, and the third most abundant metal behind aluminium and iron. It is also the fourth most abundant element in the lunar highlands. Sedimentary calcium carbonate deposits pervade the Earth's surface as fossilised remains of past marine life; they occur in two forms, the rhombohedral calcite (more common) and the orthorhombic aragonite (forming in more temperate seas). Minerals of the first type include limestone, dolomite, marble, chalk, and Iceland spar; aragonite beds make up the Bahamas, the Florida Keys, and the Red Sea basins. Corals, sea shells, and pearls are mostly made up of calcium carbonate. Among the other important minerals of calcium are gypsum (CaSO4·2H2O), anhydrite (CaSO4), fluorite (CaF2), and apatite ([Ca5(PO4)3X], X = OH, Cl, or F) The major producers of calcium are China (about 10000 to 12000 tonnes per year), Russia (about 6000 to 8000 tonnes per year), and the United States (about 2000 to 4000 tonnes per year). Canada and France are among the minor producers. In 2005, about 24000 tonnes of calcium were produced; about half of the world's extracted calcium is used by the United States, with about 80% of the output used each year. In Russia and China, Davy's method of electrolysis is still used, but is instead applied to molten calcium chloride. Since calcium is less reactive than strontium or barium, the oxide–nitride coating that results in air is stable and lathe machining and other standard metallurgical techniques are suitable for calcium. In the U.S.
=== Maternal paracetamol use === On 24 September 2025, the World Health Organization stated there is no conclusive scientific evidence linking paracetamol (acetaminophen) use during pregnancy to autism. Across multiple international health authorities, including the Society of Obstetricians and Gynaecologists of Canada, the Medicines and Healthcare products Regulatory Agency in the UK, and the European Medicines Agency, paracetemol is recommended as the first-line treatment for pain and fever during pregnancy when used at the lowest effective dose for the shortest duration. Current high-quality evidence shows no causal link between prenatal use and autism or other neurodevelopmental disorders, while untreated pain or fever poses risks to both mother and fetus. In 2025, the United States Food and Drug Administration advised physicians to minimize routine acetaminophen use during pregnancy due to unproven links to autism and ADHD, while noting it remains the safest analgesic and antipyretic option in pregnancy compared to alternatives like aspirin and ibuprofen. Very large population-based studies indicate that prenatal paracetamol use is not linked to autism, ADHD, or intellectual disability, and studies comparing siblings suggest that earlier reported links were likely due to other factors, not paracetemol itself.
Six reserve landing grounds were constructed for landing and take-off instruction to prevent congestion on the main airstrips. Later in the war, a dedicated air station was designated for the training of instructors. Small administrative units were established in South Africa at Cape Town, Durban and Port Elizabeth to handle incoming equipment and arrivals and departures of personnel. The complete pilot's course initially lasted six months, split into two months each of elementary, intermediate and advanced instruction. Ground subjects were also taught and each trainee had to fly at least 150 hours to qualify. By the end of the war each period had been shortened by a week to speed up the output of trained pilots. The trainees were mostly British, but came from all over the world. "The diversity of nationalities under training was surprising and impressive," reported one officer. "British, South African, New Zealand, Australian, Canadian, American, men from Yugoslavia, Greece, Free France, Poland, Czechoslovakia, Kenya, Uganda, Tanganyika, Fiji Isles, Malta." "[Southern Rhodesia's] part in the Commonwealth Air Training Scheme has been outstandingly fine," Sir James Ross of the British Air Ministry reported in 1942. "I say this from knowledge and without qualification. ... I know how gratefully the Air Staff in London reckon on the unfailingly regular flow of well-trained pilots and observers, course after course, month after month."
Sources: en.wikipedia.org
=== Nausea and vomiting === Intravenous dexamethasone is effective for the prevention of nausea and vomiting in people who had surgery and whose post-operative pain was treated with long-acting spinal or epidural spinal opioids. The combination of dexamethasone and a 5-HT3 receptor antagonist such as ondansetron is more effective than a 5-HT3 receptor antagonist alone in preventing postoperative nausea and vomiting.
Mukasey (1963), attorney general of the United States; former chief judge of the United States District Court for the Southern District of New York David Saxe (1963), associate justice of the Appellate Division of the New York Supreme Court, First Judicial Department and former judge on the New York Supreme Court Peter Zimroth (1963), assistant U.S. attorney for the Southern District of New York and assistant New York County district attorney, professor at the New York University School of Law Barry Kamins (1965), New York City Criminal Court judge and professor at the Fordham University School of Law and Brooklyn Law School Howard Matz (1965), senior judge of the United States District Court for the Central District of California Flemming L. Norcott Jr. (1965), former associate justice of the Connecticut Supreme Court Joel Klein (1967), assistant attorney general of the United States; chancellor of the New York City Department of Education Anthony C. Moscato (1967), acting inspector general of the Department of Justice and director of the Executive Office for United States Attorneys David M. Becker (1968), two-time general counsel of the U.S. Securities and Exchange Commission Nicholas G. Garaufis (1969), judge of the United States District Court for the Eastern District of New York and former chief counsel of the Federal Aviation Administration Jonathan D.
Sink test is a form of medical laboratory diagnostics healthcare fraud whereby clinical specimens are discarded, via a sink drain, and fabricated results are reported, without the clinical specimen actually being tested. In the United States, the prevalence of sink test laboratories in the 1980s led in part to regulation following the passage of Clinical Laboratory Improvement Amendments in 1988. While this illegal practice still occurs, it is rare within the highly regulated US lab market.
Sources: en.wikipedia.org
A number of studies suggest that the inflated rates of depression and anxiety in transgender individuals may partially be because of systematic discrimination or a lack of support. Evidence suggests that these increased rates begin to normalize when transgender individuals are accepted as their identified gender and when they live within a supportive household. Many studies report extremely high rates of suicide within the transgender community. A United States study of 6,450 transgender individuals found that 41% of them had attempted suicide, as differing from the national average of 4.6%. The very same survey found that these rates were the most high for certain demographics, with transgender youth between the ages of 18 and 24 having the highest percent. Individuals in the survey who were multiracial, had lower levels of education, and those with a lower annual income were all more likely to have attempted. Specifically, transgender males as a group are the most likely to attempt suicide, more so than transgender females. Later surveys suggest that the rate of suicidal attempts for non-binary individuals is in between the two. Transgender adults who have "de-transitioned", meaning having gone back to living as their sex assigned at birth, are significantly more likely to attempt suicide than transgender adults who have never "de-transitioned". Several studies have shown the relation between minority stress and the heightened rate of depression and other mental illness among both transgender men and women.
== External links == Media related to Earthworms at Wikimedia Commons Data related to Lumbricina at Wikispecies Chisholm, Hugh, ed. (1911). "Earthworm" . Encyclopædia Britannica (11th ed.). Cambridge University Press.
=== Underwater work === Chainsaws are used for underwater cutting by professional divers. They are usually driven by hydraulic power supplied from the surface and operated by commercial divers using surface-supplied diving equipment. Underwater chainsaw cutting may also be used by public safety divers. Hydraulic chainsaws can be used to cut wood, concrete, brick and steel if the appropriate chain is used. Underwater cutting may be done in conditions of moving water and low visibility, which can increase risk, and appropriate safety precautions and suitable procedures are required for safety. Underwater wood structures may include bridge pilings, pier, and dock timbers. Chain saws generally include an interlocking safety trigger with hand guard.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.